Dare Bioscience Inc

DARE05 Dec 2024
Healthcare
$3.36
-0.02 (-1.52%)
Lowest Today
$3.2
Highest Today
$3.36
Today’s Open
$3.36
Prev. Close
$3.28
52 Week High
$7.56
52 Week Low
$3.05
To Invest in Dare Bioscience Inc

Dare Bioscience Inc

Healthcare
DARE05 Dec 2024
-0.02 (-1.52%)
1M
3M
6M
1Y
5Y
Low
$3.2
Day’s Range
High
$3.36
3.2
52 Week Low
$3.05
52-Week Range
52 Week High
$7.56
3.05
1 Day
-
1 Week
+4.92%
1 month return
-12.56%
3 month return
-7.58%
6 month return
+709.97%
1 Year return
+821.12%
3 Years return
+77.6%
5 Years return
+318.4%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
3.31
Vanguard Total Stock Mkt Idx Inv
2.37
AMH Equity Ltd
1.15
Geode Capital Management, LLC
1.02
Vanguard Institutional Extnd Mkt Idx Tr
0.91
Renaissance Technologies Corp
0.74
Fidelity Extended Market Index
0.57

Market Status

Fundamentals
Market Cap
28.71 mln
PB Ratio
10.75
PE Ratio
0
Enterprise Value
18.88 mln
Total Assets
21.28 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.
Organisation
Dare Bioscience Inc
Employees
23
Industry
Biotechnology
CEO
Ms. Sabrina Martucci Johnson
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities